Founded in 2008, Beijing Kawin Technology Share-Holding Co., Ltd. (“Kawin”; stock code 688687) is a biopharmaceutical company focused on viral and immune diseases, and committed to offering treatment solutions based on our biotech technology platforms.
Kawin is located in the Beijing Economy-Technology Development Area (BDA), a national development zone in Beijing. Throughout our corporate development before IPO, Kawin established strategic partnerships with Legend Capital, Haitong Capital, Cybernaut, Lilly Asia Ventures (LAV), and meanwhile won several domestic honors such as Zhongguancun Top 100 High-growth Enterprise, and Beijing G20 enterprises (G20 projects). On February 8, 2021, Kawin was listed on Shanghai Stock Exchange STAR Market.
With R&D innovation as the core driver, our drug pipeline is set up mainly across innovative drugs. Our international R&D team strives their excellence in drug discover, CMC, quality control, formulations, pharmacology and clinical development. Kawin is technically specialized in the development of biological drugs from the beginning to the end by our own R&D force.
Kawin owns 7 GMP production lines for the production of biological and chemical products. The biological product lines include Small Volume Parenteral Solutions, Lyophilized Powder for Injection, and Effervescent Tablets. The chemical product lines include Small Volume Parenteral Solutions, Lyophilized Powder for Injection, Tablets, and Capsules. Among them, the chemical product lines of terminally sterilized injection received international GMP certification (PIC/S standard).
Kawin now has variety of commercialized products, such as Recombinant Human Interferon α2b Injection (凯因益生®), Compound Glycyrrhizin Capsules (凯因甘乐®), and Recombinant Human Interferon α2b Vaginal Effervescent Tablets (金舒喜®), whose market shares rank among the top within the industry. In addition, as the part of “Kawin Scheme”-- the 1st local full oral and pan-genotype scheme to achieve high cure rate of Hepatitis C, our innovative drug Coblopasvir Hydrochloride Capsules (凯力唯®) in combination with our Sofosbuvir Tablets (赛波唯®) has been included in the China's National Reimbursement Drug List (NRDL). Nowadays the majority of domestic hepatitis C treatment schemes are gene-specific. The launch of Kawin Scheme broke up the monopoly of imported HCV pan-genotype DAAs drugs and created more treatment option as well as benefits for HCV patients.
Oriented by clinical treatment needs, Kawin strives to become a pioneer in the antiviral and immune area and dedicates into healthcare industry by developing innovative drugs and offering deliverable-based treatment solutions.